U.S. President Donald Trump has signed a new executive order aimed at accelerating research and regulatory review of psychedelic-based medical treatments, marking a major federal shift in how certain previously restricted substances may be used in mental health care.
The order directs the U.S. Food and Drug Administration to fast-track evaluation of drugs such as ibogaine, a psychedelic compound that has shown early promise in treating conditions including post-traumatic stress disorder (PTSD), particularly among military veterans.
Under the directive, federal agencies will also increase support for clinical trials and research into psychedelic therapies. The administration announced $50 million in funding dedicated specifically to ibogaine research, signalling growing government interest in alternative mental health treatments.
Health Secretary Robert F. Kennedy Jr. has been a vocal supporter of exploring psychedelic compounds as potential treatments for depression, addiction, and trauma-related disorders. Supporters of the initiative argue that traditional approaches have not been effective for all patients.
FDA Commissioner Marty Makary said regulatory decisions on psychedelic-based therapies could come as early as this summer, depending on the outcomes of ongoing clinical trials.
The move represents a significant policy shift, as substances like ibogaine remain largely illegal in many jurisdictions due to their hallucinogenic effects and potential safety risks. However, researchers and veteran advocacy groups have increasingly pushed for controlled medical use under strict supervision.
If successful, the reforms could pave the way for broader acceptance of psychedelic-assisted therapies within mainstream healthcare systems, particularly for treatment-resistant mental health conditions.
